

**Seretide 50 Evohaler (Salmeterol xinafoate 25mcg/
fluticasone propionate 50mcg) (No. 108/04)**

GlaxoSmithKline UK

Product Update

12 July 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE: following an abbreviated submission

Seretide 50 Evohaler™ is accepted for use within NHS Scotland for the regular treatment of asthma where use of a combination of the long-acting beta agonist salmeterol and the inhaled corticosteroid fluticasone is appropriate for a child aged 4-12 years.

The acquisition cost of the combination product is less than for the individual components given by aerosol inhalation and for the combination given by Accuhaler™.

Professor D H Lawson
Chairman